• AgoraVox sur Twitter
  • RSS
  • Agoravox TV
  • Agoravox Mobile


Commentaire de njama

sur Médicaments anticancéreux peu efficaces souvent toxiques et hors de prix : réponses aux questions des lecteurs


Voir l'intégralité des commentaires de cet article

njama njama 22 novembre 2017 15:04

Le GcMAF est nommé sous le code  EF-022 **il fait l’objet d’études officielles

Safety Study of EF-022 ( Modified Vitamin D Binding Protein Macrophage Activator) in Subjects With Advanced Solid Tumors
ClinicalTrials.gov Identifier :
NCT02052492
First Posted : February 3, 2014
Last Update Posted : June 20, 2017
https://clinicaltrials.gov/ct2/show/NCT02052492

** Modified Vitamin D Binding Protein Macrophage Activator EF-022

Definition : A modified version of vitamin D binding protein (VDBP ; Gc protein) macrophage activator, with potential antineoplastic and anti-angiogenic activities. Upon administration, modified VDBP-macrophage activator EF-022, acting in a similar manner as VDBP-macrophage activating factor (GcMAF), is able to activate tumoricidal macrophages, thereby enhancing the killing and eradication of cancer cells. In addition, EF-022 may inhibit tumor cell proliferation, migration and angiogenesis. VDBP is a glycoprotein and precursor for macrophage activating factor (MAF), which promotes macrophage activation ; however VDBP can be deglycosylated by serum alpha-N-acetylgalactosaminidase, which is secreted from cancerous cells, and cannot be converted to MAF. Thus, the macrophage activation cascade is often impaired in tumor cells and plays a key role in tumor immunosuppression. Modification of VDBP stabilizes MAF.
 https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C131824

Répondre Signaler un abus

Voir ce commentaire dans son contexte


Derniers commentaires




Palmarès